Posted by Michael Wonder on 11 Mar 2016
Genmab announces submission of supplemental biologics license application to FDA for ofatumumab in combination with fludarabine and cyclophosphamide for relapsed CLL
10 March 2016 - The application was submitted by Novartis under the ofatumumab collaboration between Novartis and Genmab.
For more details, go to: http://ir.genmab.com/releasedetail.cfm?ReleaseID=959983
